CASE REPORT article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1541209

This article is part of the Research TopicPathophysiology and Therapeutic Strategies for Oral and Head and Neck CancersView all 11 articles

Efficacy of Toripalimab in Combination with Anlotinib in Recurrent Undifferentiated Pleomorphic Sarcoma of the Sinonasal: A Case Report with Biomarker Analysis

Provisionally accepted
Fang WuFang Wu1Junqiao FengJunqiao Feng2Hong WangHong Wang2Shan WangShan Wang2Xiaoguang CuiXiaoguang Cui2Ying LiuYing Liu1Kaihong YeKaihong Ye3Rick Francis ThorneRick Francis Thorne3Xu Dong ZhangXu Dong Zhang3Ting LaTing La2*
  • 1Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi Province, China
  • 2The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China
  • 3Henan Provincial People's Hospital, Zhengzhou, Henan Province, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Background: Soft tissue sarcoma (STS) typically originates in the muscles and is associated with a poor prognosis. Undifferentiated pleomorphic sarcoma (UPS) is the most commonly diagnosed subtype of STS; however, UPS occurring in the sinonasal region is exceedingly rare and lacks effective treatment options.Objective: This case report presents a patient with sinonasal UPS who experienced disease progression after surgery and chemotherapy but showed a positive response to combination therapy with toripalimab and anlotinib. Additionally, it explores the underlying biomarkers associated with this case.Case: A 63-year-old female with no significant past medical history was diagnosed with sinonasal UPS. The lesions recurred despite seven extensive surgical resections, and standard chemotherapy failed to control the disease, leading to progressive disease (PD).Results: The patient was treated with a combination of toripalimab and anlotinib, resulting in a significant partial response (PR) after just two cycles. Continued PR was observed after an additional six cycles, indicating the potential for a prolonged response with ongoing therapy. Genotyping and immunohistochemistry revealed that the sarcoma cells were rapidly dividing and enriched in vasculature prior to systemic treatment.Conclusion: These findings suggest that the combination of toripalimab and anlotinib may be an effective treatment option for advanced cases of UPS in the sinonasal region.

Keywords: undifferentiated pleomorphic sarcoma, Recurrence, Toripalimab, Anlotinib, case report

Received: 07 Dec 2024; Accepted: 17 Apr 2025.

Copyright: © 2025 Wu, Feng, Wang, Wang, Cui, Liu, Ye, Thorne, Zhang and La. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ting La, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710049, Shaanxi Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material